12.08.21
Gnosis by Lesaffre has launched a new version of its renowned vitamin K2 (menaquinone) ingredient vitaMK7, which now contains a new protective matrix for enhanced stability in complex formulations. The protective matrix does not use a coating, additives, or additional ingredients, the company reports, noting that finished product formulations containing this vitamin require expertise rather than a one-size-fits-all solution.
“Stability is a constant issue facing commercial partners with the desire to create complex vitamin k2 formulations. Historically, our R&D team has been able to guide them through the process to ensure their products were stable,” Dr. Sophie Legrain-Raspaud, global research and applications director with Gnosis by Lesaffre, said. “With VitaMK7 Matrix, that process is now more efficient because the matrix carrier embeds the K2 as MK7 particles in the product, thus leading to products hitting the market much faster.”
Moisture and mineral salts represent two critical variables for vitamin K2 degradation, the company said in the announcement. For these reasons, protective technology to shelter menaquinone molecules during shelf life is a driving need.
In addition to providing a more predictable formulation process for complex K2 products, the vitaMK7 matrix also offers improved homogeneity, stability in mineral complexes, and the ability for formulas to keep a short and unchanged list of ingredients with no additives.
“This is an important improvement we are excited to share with our commercial partners and the global market,” Xavier Berger, global market manager, said. “Enhancing protection of the MK-7 molecule is an important element for those seeking to explore complex formulations that will truly impact health. Our team has worked extensively to ensure that our innovation was truly unique to the market, and most importantly, that it would have a tremendous impact on those with a vision for what the market needs.”
“Stability is a constant issue facing commercial partners with the desire to create complex vitamin k2 formulations. Historically, our R&D team has been able to guide them through the process to ensure their products were stable,” Dr. Sophie Legrain-Raspaud, global research and applications director with Gnosis by Lesaffre, said. “With VitaMK7 Matrix, that process is now more efficient because the matrix carrier embeds the K2 as MK7 particles in the product, thus leading to products hitting the market much faster.”
Moisture and mineral salts represent two critical variables for vitamin K2 degradation, the company said in the announcement. For these reasons, protective technology to shelter menaquinone molecules during shelf life is a driving need.
In addition to providing a more predictable formulation process for complex K2 products, the vitaMK7 matrix also offers improved homogeneity, stability in mineral complexes, and the ability for formulas to keep a short and unchanged list of ingredients with no additives.
“This is an important improvement we are excited to share with our commercial partners and the global market,” Xavier Berger, global market manager, said. “Enhancing protection of the MK-7 molecule is an important element for those seeking to explore complex formulations that will truly impact health. Our team has worked extensively to ensure that our innovation was truly unique to the market, and most importantly, that it would have a tremendous impact on those with a vision for what the market needs.”
